Category: HypertensionSyndicate content

Rox Medical closes enrollment in hypertension 'stent' trial

April 14, 2014 by Brad Perriello

Rox Medical closes enrollment in a clinical trial of its Rox Coupler, a stent-like device designed to treat hypertension by connecting the femoral vein and the femoral artery.

Rox Medical closes enrollment in hypertension 'stent' trial

Rox Medical said it closed enrollment in a 100-patient clinical trial of its Rox Coupler device, designed to treat hypertension by connecting the femoral artery and the femoral vein.

CEO Rodney Brenneman told MassDevice.com that Rox Medical, a Stanford spinout established in 2004 to pursue several indications including chronic obstructive lung disease and heart failure, noticed a dramatic effect on high blood pressure in COPD patients implanted with the device.

Hypertension: Docs turn on renal denervation | MassDevice.com On Call

April 10, 2014 by Arezu Sarvestani

U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.

MassDevice.com On Call

MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 by Arezu Sarvestani

More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.

fired/hired

The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

March 31, 2014 by Brad Perriello

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said Saturday at the American College of Cardiology's annual conference.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

ACC 2014: Medtronic details Symplicity renal denervation data

March 29, 2014 by Ingrid Mezo

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said today at the American College of Cardiology's annual conference.

YYmeta

Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

Medtech gears up for Medtronic's RDN trial results | MassDevice.com On Call

March 28, 2014 by Brad Perriello

All eyes will be on Medtronic this weekend for the 1st release of data from its failed Symplicity HTN-3 renal denervation trial at the American College of Cardiology's annual meeting in D.C.

MassDevice.com On Call

MASSDEVICE ON CALL — The medical device world will be watching intently this weekend as Medtronic (NYSE:MDT) releases data for the 1st time from a failed clinical trial of its Symplicity renal denervation device.

Hypertension: Cordis lands Euro approval for Renlane renal denervation

February 21, 2014 by Arezu Sarvestani

Johnson & Johnson subsidiary Cordis Corp. wins European CE Mark approval for its Renlane renal denervation system for treating patients with resistant hypertension.

Hypertension: Cordis lands Euro approval for Renlane renal denervation

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp